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Abstract
Neoplasms of extra-thymic T-cell origin represent a rare and difficult population character-
ized by poor clinical outcome, aggressive presentation, and poorly defined molecular char-
acteristics. Much work has been done to gain greater insights into distinguishing features
among malignant subtypes, but there also exists a need to identify unifying characteristics
to assist in rapid diagnosis and subsequent potential treatment. Herein, we investigated
gene expression data of five different mature T-cell lymphoma subtypes (n = 187) and
found 21 genes to be up- and down-regulated across all malignancies in comparison to
healthy CD4+ and CD8+ T-cell controls (n = 52). From these results, we sought to character-
ize a role for caveolin-1 (CAV1), a gene with previous description in the progression of both
solid and hematological tumors. Caveolin-1 was upregulated, albeit with a heterogeneous
nature, across all mature T-cell lymphoma subtypes, a finding confirmed using immunohis-
tochemical staining on an independent sampling of mature T-cell lymphoma biopsies (n =
65 cases). Further, stratifying malignant samples in accordance with high and low CAV1
expression revealed that higher expression of CAV1 in mature T-cell lymphomas is analo-
gous with an enhanced inflammatory and invasive gene expression profile. Taken together,
these results demonstrate a role for CAV1 in the tumor microenvironment of mature T-cell
malignancies and point toward potential prognostic implications.
Introduction
Mature T-cell lymphomas are a heterogeneous group of malignancies representing 10–15% of
all non-Hodgkin’s lymphomas with 17,850 cases diagnosed in the United States between 2003–
2012 [1, 2]. Mature T-cell lymphomas are characterized by aggressive growth, generally poor
clinical outcome, and only a paucity of reported genetic abnormalities [3–6]. Currently, the
World Health Organization recognizes a number of mature T-cell lymphoma subtypes, includ-
ing: angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL),
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The state of research on mature T-cell lymphomas aims to enhance the recognition of
molecular subtypes, thereby improving diagnostics; ultimately these produce improved prog-
nostic models to aide in treatment [8–13]. Advances in the area of diagnostics lead to increased
classification rates diverging from PTCL-NOS [8, 10, 11], which has been considered a “waste-
basket” category [7]. While molecular diagnostics to improve the classification rates of T-cell
lymphoma subtypes have obvious value in terms of targeted treatment, understanding unifying
characteristics of a group of malignancies sharing an extra-thymic cell-of-origin is warranted.
Therefore, an enhanced understanding of the shared molecular underpinnings of neoplasms of
T-cell origin could lead toward the development of novel combinatorial therapies and informa-
tion regarding the basic biology of mature T-cell lymphomas.
The goal of this study was to conduct an expansive meta-analysis (sometimes termed mega-
analysis) [14] of microarray data on mature nodal and splenic T-cell lymphomas to construct a
gene signature shared across all subtypes. To this end, we mined the NCBI GEO DataSets
(Table 1) for chip-matched, mature T-cell lymphoma samples (n = 187) and healthy CD4+ and
CD8+ T-cell controls (n = 52) with focus on genes annotated to function in T-cell receptor sig-
naling, T-cell co-stimulation, T-cell homeostasis, and T-cell differentiation in the gene ontol-
ogy (GO) directory to mitigate background from the stromal compartment. The
abovementioned genetic findings were then corroborated at the protein level using human
biopsies of mature T-cell lymphoma cases (n = 130 core biopsies from n = 65 unique cases).
Herein, presented are the findings of the genetic analysis with an increased focus on caveo-
lin-1 (CAV1), a gene seen heterogeneously upregulated across all T-cell lymphoma subtypes,
mimicking data observed in chronic lymphocytic leukemia, a B-cell neoplasm [15, 16, 17].
These data support a correlation between CAV1 and the promotion of an inflammatory and
invasive phenotype in mature T-cell lymphomas. Future research will be required to determine
whether CAV1 is directly involved in the process.”
Table 1. Publically available, chip-matched GEO DataSets of mature T-cell lymphomas and healthy
CD4+ and CD8+ T cells utilized for gene expression profiling.
GEO
Accession
Samples Utilized (n-value) PMID
GSE43017 Healthy Samples: CD4+ T cell (5) N/A
GSE6338 Malignant Samples: PTCL-NOS (28), AITL (6), ALCL (6) Healthy
Samples: CD4+ T cell (5), CD8+ T cell (5),
17304354
GSE61399 Healthy Samples: CD4+ T cell (3) N/A
GSE14879 Malignant Samples: ALCL (9) 19657361,
24376854
GSE19067 Malignant Samples: HSTL (4) 21052088
GSE19069 Malignant Samples: AITL (37), ALCL (30), ATLL (13), PTCL-NOS (50)
Healthy Samples: CD4+ T cells (1)
19965671
GSE25087 Healthy Samples: CD4+ T cell (3) 21164017
GSE31773 Healthy Samples: CD4+ T cell (8), CD8+ T cell (8) 21917308
GSE36769 Healthy Samples: CD4+ T cell (4) 23778140
GSE49954 Healthy Samples CD4+ T cell (5), CD8+ T cell (5) 24130824
GSE57944 Malignant Samples: HSTL (4) 25057852
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ATLL, adult T-cell
leukemia/lymphoma; HSTL, hepatosplenic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not
otherwise specified; PMID, PubMed identifier
doi:10.1371/journal.pone.0142682.t001
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Results
Construction of a shared T-cell compartment gene signature across
mature T-cell lymphomas
In order to delineate a shared T-cell compartment signature among a diverse grouping of
mature T-cell lymphomas, we conducted differential expression analyses of the five different
mature T-cell lymphoma subtypes collected, focusing on GO annotations specific to T-cell
biology. We analyzed each T-cell lymphoma subtype separately, with a final manual compila-
tion of genes found to be differentially expressed across all subtypes. This analysis revealed an
up-regulation of 6 genes (namely CAV1, CCNB2, ENAH, PSEN2, THY1, TNFRSF21) (Fig 1A)
and a down-regulation of 15 genes (namely BCL10, CD3G, CD5, FOXP1, IL23A, ITK, LAT,
PAG1, PDE4B, PRKCQ, RICTOR, STAT5A, TNFRSF14, TSC22D3, UBASH3A) (Fig 1B) that
were observed to be differentially expressed (p< 0.001, FDR< 0.001) in all T-cell lymphoma
subtypes (Table 2). Further, 52 genes were found to either be up- or down-regulated in at least
3 out of 5 of the analyzed subtypes (S1 Table).
To show the robust nature of these findings, the 21 pan-regulated genes were used for class
prediction using the top-scoring pairs (TSP) method [18]. This pairwise comparison method
selects a family of gene pairs and classifies samples based on a decision involving the compari-
son of the ratio of mRNA abundance for selected gene pairs [18]. Of the 21 candidate genes,
TSP scored the expression ratio of CAV1 (Fig 1C) and BCL10 (Fig 1D) to hold the greatest
magnitude of change. Using the CAV1-BCL10 classifier, T-cell lymphoma samples were classi-
fied with 98.4% sensitivity and 88.5% specificity (S2 Table). These results suggest that the
inverse expression of CAV1 and BCL10may assist in the diagnosis of mature T-cell lympho-
mas, and can be attributable to all analyzed subtypes.
Stratification of mature T-cell lymphomas by expression of Caveolin-1
As previously reported, higher CAV1 expression in B-cell lymphomas leads to a more aggres-
sive disease [15, 16] with an inferior overall survival among patients with higher CAV1 expres-
sion [15]. Therefore, we decided to further investigate the differences between CAV1-High and
CAV1-Low expressing mature T-cell lymphoma samples in an effort to characterize the impact
of CAV1 on the tumor microenvironment (TME). Analysis of CAV1 expression using
212097_at probe signal intensity revealed that all mature T-cell lymphoma subtypes analyzed
have a higher mean expression of CAV1 (p< 0.001, FDR< 0.001) as compared to healthy
CD4+ and CD8+ T-cell controls (Fig 1C). However, as expected, there exists a heterogeneous
expression of CAV1 amongst the malignant samples. To stratify samples into the abovemen-
tioned groups, healthy controls and malignant samples were pooled, respectively. Moreover, a
CAV1-Low expression threshold was calculated based on the distribution of CAV1 expression
in healthy samples (Fig 2A). Using this threshold, 67% (125/187) of mature T-cell lymphoma
samples were classified as CAV1-High (Fig 2B). For each T-cell lymphoma subtype: 77% (33/
43) of AITL samples, 47% (21/45) of ALCL samples, 85% (11/13) of ATLL samples, 75% (6/8)
of HSTL samples, and 69% (54/78) of PTCL-NOS samples were classified as CAV1-High.
The CAV1-High tumor microenvironment is enriched in genes involved
in the immune response, chemokine/cytokine activity, and invasive
genes
As shown above in Fig 2, mature T-cell lymphoma samples highly express CAV1, with 67% of
samples harboring expression that is 2 standard deviations above mean CAV1 expression in
CD4+ and CD8+ T cells. However, 33% of samples express CAV1 within a healthy range, with
CAV1 Expression across Mature T-Cell Lymphomas
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no one-subtype exclusively harboring high CAV1 expression. To investigate the impact of
higher CAV1 expression on the TME (i.e. the whole tissue sample), we used the class compari-
son among groups of arrays method. To expand our analysis to the TME, yet reduce inter-
malignancy variation, only genes significantly correlated to CAV1 expression were considered
(see Materials and Methods). Of the 7,170 genes analyzed, we report that 2,624 genes were dif-
ferentially expressed (p< 0.001, FDR< 1% at 99% confidence) between the two classes, 1,758
Fig 1. Construction of a shared T-cell compartment gene signature acrossmature T-cell lymphomas. (A) Heatmap of genes (n = 6) significantly
(p < 0.001, FDR < 0.001) upregulated across all T-cell lymphoma subtypes as compared with healthy controls. Genes are mean-centered, standard-
deviation scaled, and clustered according to average linkage. Samples are aligned according to healthy (purple bar) or malignant (orange bar) designations.
(B) Heatmap of genes (n = 15) significantly (p < 0.001, FDR < 0.001) downregulated across all T-cell lymphoma subtypes as compared to healthy controls.
Genes are mean-centered, standard-deviation scaled, and clustered according to average linkage. Samples are aligned according to healthy (purple bar) or
malignant (orange bar) designations. (C) Boxplot of normalized 212097_at (CAV1) probe signal across sample types. Continuous line represents median
value of sample, discontinuous line represents mean value. (D) Boxplot of normalized 1557257_at (BCL10) probe signal for representation. Continuous line
represents median value of sample, discontinuous line represents mean value.
doi:10.1371/journal.pone.0142682.g001
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(67%) of which were overexpressed in the CAV1-High group. For analysis, we input the fold-
changes values from the genes found differentially expressed into the PANTHER gene analysis
tool [19, 20]. PANTHER enrichment analyses reveal the CAV1-High TME to be enriched in
genes annotated to be involved in chemokine/cytokine activity, invasion (migration/motility/
movement), and immune processes (Table 3). Chemokine/cytokine activity featured enrich-
ments in biological processes, molecular functions, and the chemokine protein family. Invasive
activity was found to harbor enrichments in biological processes and enrichment of the integ-
rin signaling pathway (S1 Fig). Immune processes featured enrichments in biological processes.
Furthermore, overrepresentation analysis revealed significant (p< 0.05) overrepresentation of
genes upregulated in CAV1-High conditions to be involved in the PANTHER pathways for
inflammation mediated by chemokine and cytokine signaling (S2 Fig) and angiogenesis (S3
Fig). As CAV1 is overexpressed in mature T-cell lymphomas, the tumor microenvironment
adopts a gene expression profile indicative of increased inflammation and metastatic potential,
as demonstrated above. This phenotype suggests a correlation between CAV1expression and
increased inflammation in the tumor microenvironment of T-cell lymphomas. Increased
Table 2. Genes significantly up- or down-regulated across all mature T-cell lymphoma subtypes as compared with healthy CD4+ and CD8+ T-cell
controls.
Gene Name Symbol Chromosomal
Location
AITL Fold-
Change
ALCL Fold-
Change
ATLL Fold-
Change
HSTL Fold-
Change
PTCL-NOS
Fold-Change
Caveolin-1 CAV1 7q31.1 16.33 12.52 38.17 34.41 16.33
Cyclin B2 CCNB2 15q22.2 7.55 8.93 13.99 9.65 7.55
Thy-1 cell surface antigen THY1 11q23.3 13.65 12.98 9.46 2.46 13.65
Tumor necrosis factor receptor
superfamily member 21
TNFRSF21 6p21.1 6.3.8 6.27 5.34 9.30 6.38
Enabled homolog ENAH 1q42.12 5.62 5.36 2.52 22.63 5.62
Presenilin 2 PSEN2 1q42.13 2.94 4.77 2.26 3.39 2.94
3g molecule, gamma (CD3-TCR
complex)
CD3G 11q23 -3.01 -6.81 -1.65 -2.02 -3.00
Tumor necrosis factor receptor
superfamily member 14
TNFRSF14 1p36.32 -1.49 -1.58 -1.69 -1.99 -1.49
RPTOR independent companion of
MTOR, complex 2
RICTOR 5p13.1 -2.42 -4.36 -1.75 -2.25 -2.42
Linker for activation of T-cells LAT 16p11.2 -2.91 -3.61 -1.92 -3.76 -2.91
CD5 molecule CD5 11q13 -4.12 -6.55 -2.10 -17.27 -4.11
Interleukin 23, alpha subunit p19 IL23A 12q13.3 -3.26 -3.50 -2.23 -4.51 -3.26
IL2-inducible T-cell kinase ITK 5q31-q32 -3.67 -10.78 -2.36 -2.70 -3.67
Signal transducer and activator of
transcription 5A
STAT5A 17q11.2 -2.14 -2.11 -2.50 -2.63 -2.14
TSC22 domain family, member 3 TSC22D3 Xq22.3 -5.66 -6.63 -2.56 -4.07 -5.66
Ubiquitin-associated and SH3 domain-
containing protein A
UBASH3A 21q22.3 -2.43 -4.27 -2.86 -6.97 -2.43
Protein kinase C theta PRKCQ 10p15 -2.98 -8.26 -3.58 -2.92 -2.98
Forkhead box P1 FOXP1 3p14.1 -4.90 -3.96 -3.69 -3.40 -4.90
Phosphoprotein membrane anchor
with glycosphingolipid microdomains 1
PAG1 8q21.13 -3.81 -2.32 -4.30 -3.69 -3.81
B-cell CLL/lymphoma 10 BCL10 1p22 -4.96 -7.82 -6.54 -7.15 -4.96
Phosphodiesterase 4B, cAMP-specific PDE4B 1p31 -4.21 -3.55 -7.44 -3.42 -4.21
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; HSTL, hepatosplenic T-cell
lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified
doi:10.1371/journal.pone.0142682.t002
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Fig 2. T-cell lymphomas can be divided intoCAV1-High andCAV-1 Low subgroups. (A) Boxplot of normalized 212097_at (CAV1) probe signal between
pooled healthy controls and malignant samples. Continuous line represents median value, discontinuous line represents mean. Red line represents
threshold for CAV1-High or CAV1-Low expression determination and is set 2 standard deviations above the healthy T-cell mean value. (B) Classification of
CAV1-High andCAV1-Low samples according to expression threshold. Solid bars and above-bar values represent percentage of CAV1-High samples per
subtype. 67% (125/187) of all malignant samples were classified as CAV1-High. 77% (33/43) of AITL samples, 47% (21/45) of ALCL samples, 85% (11/13) of
ATLL samples, 75% (6/8) of HSTL samples, 69% (54/78) of PTCL-NOS samples.
doi:10.1371/journal.pone.0142682.g002
Table 3. PANTHER enrichment analysis of genes upregulated in theCAV1-High tumor microenvironment.
Immune Enrichment GO Annotation Number of Genes OverUnder p-value1
Biological Process: Regulation Of Leukocyte Activation 59 + 2.10E-02
Activation Of Immune Response 65 + 3.32E-02
Immune Effector Process 76 + 1.03E-04
Positive Regulation Of Immune Response 81 + 2.61E-02
Regulation Of Immune Response 125 + 4.92E-02
Regulation Of Immune System Process 189 + 2.85E-04
Immune Response 194 + 1.00E-04
Chemokine/Cytokine Enrichment GO Annotation Number of Genes OverUnder p-value
Biological Process: Cell Chemotaxis 24 + 9.08E-05
Regulation Of Chemotaxis 30 + 2.81E-02
Cytokine-Mediated Signaling Pathway 65 + 1.33E-03
Inflammatory Response 68 + 1.21E-02
Cellular Response To Cytokine Stimulus 86 + 7.25E-05
Response To Cytokine 106 + 3.97E-06
Molecular Function: Chemokine Activity 11 + 2.79E-03
Chemokine Receptor Binding 12 + 1.11E-03
Protein Family: Chemokine 9 + 3.03E-03
Invasion Enrichment GO Annotation Number of Genes OverUnder p-value1
Biological Process: Regulation Of Leukocyte Migration 23 + 4.32E-02
Extracellular Matrix Organization 72 + 2.88E-03
Regulation Of Cell Migration 98 + 8.69E-04
Regulation Of Cell Motility 104 + 7.91E-04
Regulation Of Cellular Component Movement 112 + 5.30E-04
Pathway: Integrin Signaling Pathway 36 + 4.44E-02
1 p-values calculated using the Bonferroni correction
doi:10.1371/journal.pone.0142682.t003
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inflammation could lead to increased tumor burden and recruitment of non-neoplastic cells
[21, 22], potentially leading to a more aggressive disease.
Immunohistochemical analysis on an independent sampling of mature
T-cell lymphomas
To investigate our genetic findings at the protein level, we purchased LY6161 high-density lym-
phoma and normal lymph node tissue arrays from U.S. Biomax, Inc. These tissue arrays con-
tained n = 25 normal lymph nodes and n = 130 core biopsies from n = 65 unique, mature T-
cell lymphoma patients (8 AITL, 14 ALCL, and 43 PTCL-NOS patients, respectively). Separate
tissue array slides were stained with antibodies directed towards: BCL10, CAV1, CD90 (Thy-
1), GILZ (TSC22D3), in addition to standard hematoxylin and eosin staining. Summarized
analysis of immunohistochemical staining can be found in Table 4, detailed analysis of individ-
ual samples can be found in S3 Table, with representative imaging found in Fig 3.
For BCL10 staining, 88% (7/8) of AITL samples, 93% (13/14) of ALCL samples, and 91%
(39/43) PTCL-NOS samples were scored positive for lymphoid staining. 2 ALCL samples and
1 PTCL-NOS sample were scored light in comparison to other positive samples in terms of
lymphoid staining. 1 PTCL-NOS sample was scored with light stromal/non-lymphoid staining,
and 1 AITL sample, 1 ALCL sample, and 3 PTCL-NOS samples were scored negative for lym-
phoid staining. For CAV1 staining, 63% (5/8) of AITL samples, 43% (6/14) of ALCL samples,
and 58% (25/43) of PTCL-NOS samples were scored positive for lymphoid staining. 1 AITL
sample was negative for CAV1 staining. 2 AITL samples, 8 ALCL samples, and 18 PTCL-NOS
samples were positive for stromal/non-lymphoid staining. For GILZ staining, 100% (8/8) of
AITL samples, 93% (13/14) of ALCL samples, and 93% (40/43) PTCL-NOS samples were
scored positive for lymphoid staining. 2 AITL samples, 1 ALCL sample, and 7 PTCL-NOS sam-
ples were scored light in comparison to other positive samples in terms of lymphoid staining. 1
ALCL sample was scored with stromal/non-lymphoid staining, and 3 PTCL-NOS samples
were scored negative for presence of stain. For CD90 staining, 75% (6/8) of AITL samples, 36%
(5/14) of ALCL samples, and 42% (18/43) of PTCL-NOS samples were scored positive for lym-
phoid staining. 6 ALCL samples and 13 PTCL-NOS samples were scored positive for stromal/
non-lymphoid staining, and 2 AITL samples, 3 ALCL samples, and 12 PTCL-NOS samples
were scored negative for presence of stain.
The results from protein staining of the TMAs support the genetic findings two-fold. First,
as the GEP data are publically derived, routine qPCR validations are unavailable and a second-
ary confirmation of protein analysis is needed. The protein findings support the GEP results
through reaffirming that the GEP data are originating from tumor lymphocytes within the
samples and are not strictly artifacts of stromal components, as the biopsy samples used for the
GEP analyses were neither flow sorted nor laser micro-dissected and we can determine the
localization of staining based on histology of the TMA. These findings are supported by the
staining patterns displayed in Fig 3 showing positive staining in tumor lymphocytes as opposed
to solely stromal and/or non-lymphocyte staining. Secondly, as the TMA samples are
completely distinct in patient origin to those used in the GEP we can see that the GEP results,
this shows the strength of these findings in that they are consistent between genomic and pro-
tein expression across a large sample size of cases of lymphoma.
Long non-coding RNA 273 is computationally predicted to interact with
members of a CAV1-interaction network
Strikingly, an uncharacterized long, intergenic non-coding RNA (LINC00273) was found to be
expressed 3-fold higher in CAV1-Low T-cell lymphoma samples compared to CAV1-High (Fig
CAV1 Expression across Mature T-Cell Lymphomas
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4A). As long non-coding RNAs have been implicated in RNA-protein binding complexes, we
sought to investigate if LINC00273 represented a potential RNA-protein interaction (RPI) part-
ner with CAV1 and CAV1-interacting proteins, as CAV1 expression was the basis upon which
the abovementioned groups were stratified. Using STRING v10, we determined the predicted
CAV1-interactions networks for genes upregulated in both CAV1-High (Fig 4B) and CAV1-
Low groups (Fig 4C). Of the 1,758 genes upregulated in CAV1-High samples, 38 proteins were
modeled to interact (either direct, or indirect) with CAV1 (Fig 4B). The CAV1-High interac-
tion network featured 100 protein-protein interactions, of which the protein constituents were
found to be enriched in GO biological processes for regulation of cell differentiation
(p = 2.7x10−4), cell migration (p = 4.2x10−4), cell proliferation (p = 7.2x10−4), apoptotic pro-
cesses (p = 2.87x10−4), and the KEGG TGF-beta signaling pathway (p = 1.9x10−6). Conversely,
only 4 proteins of the 866 genes upregulated in CAV1-Low samples were modeled to interact
with CAV1 (Fig 4C). This protein network featured 4 protein-protein interactions and was
Table 4. Summary of diagnoses, patient characteristics, and staining properties of T-cell lymphoma histological samples from the Ly6161 tissue
microarray from U.S. Biomax, Inc.
Diagnosis Sample # Median Age1 % Male BCL102 CAV12 GILZ2 CD902
Anaplastic large cell lymphoma 14 45 50% (7/14) 93% (13/14) 43% (6/14) 93% (13/14) 36% (5/14)
Angioimmunoblastic T-cell lymphoma 8 50 63% (5/8) 88% (7/8) 63% (5/8) 100% (8/8) 75% (6/8)
Peripheral T-cell lymphoma-NOS 43 41 53% (23/43) 91% (39/43) 58% (25/43) 93% (40/43) 42% (18/43)
1 Age reported in years
2 Percentages reflect staining observed in lymphoid cells
doi:10.1371/journal.pone.0142682.t004
Fig 3. Immunohistochemical staining of mature T-cell lymphoma biopsies. Representative positive and negative lymphoid-staining samples for BCL10,
CAV1, GILZ, and CD90 are presented. All images were taken at 60x magnification. No healthy lymph nodes were negative for BCL10 lymphoid staining.
Yellow arrowheads in ALCL positive sample point toward punctate CAV1 staining in hallmark horse-shoe nuclei tumor cells.
doi:10.1371/journal.pone.0142682.g003
CAV1 Expression across Mature T-Cell Lymphomas
PLOSONE | DOI:10.1371/journal.pone.0142682 November 13, 2015 8 / 22
found to be enriched for the GO biological processes of fibroblast growth factor receptor sig-
naling (p = 1.91x10−4) and ERBB signaling (p = 5.46x10−4).
Using available prediction methods for RPI, we sought to achieve a consensus computa-
tional prediction concerning the interaction potential of LINC00273 in CAV1-interaction net-
works. The lncPro [23], RPISeq (both Random Forrest [RPISeq-RF] and Support Vector
Machine [RPISeq-SVM] output) [24], and RPI-Pred [25] programs were used in the above-
mentioned RPI-prediction analysis. Of the 43 proteins evaluated for RPI, lncPro scored 100%
of potential proteins as interacting, RPISeq-RF scored 100% as interacting, RPISeq-SMV
scored 7% (3/43) as interacting, and RPI-Pred scored 100% as interacting. Detailed results can
be found in Table 5. These computational data support a potential interaction between
LINC00273 and members of a CAV1-interaction network. However, the exact functional con-
sequences of these interactions are not fully understood. Potentially, LINC00273may serve as a
scaffold, increasing the stability or proximity of the CAV1-interacting proteins, or may hold
regulatory properties over its interacting proteins.
Fig 4. Long non-Coding RNA 273 is computationally predicted to interact with members of a CAV1-interaction network. (A) Boxplot of normalized
AFFX-HUMRGE/M10098_5_at (LINC00273) probe signal for CAV1-Low andCAV1-High expression groups. Continuous line represents median value,
discontinuous line represents mean value. (B) CAV1-interacting proteins upregulated in theCAV1-High expression group. Interaction network viewed in
String evidence view, connection lines are defined by in-Fig box. (C) CAV1-interacting proteins upregulated in the CAV1-Low expression group. Interaction
network viewed in String evidence view, connection lines are defined by in-Fig box.
doi:10.1371/journal.pone.0142682.g004
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Table 5. Computational predictions for RNA-protein interactions between LINC00273 and CAV1-interacting proteins.
Protein Symbol UniProt Sequence
ID
lncPro1 RPISeq-
RF2
RPISeq-
SVM3
RPI-Pred
Adenylate cyclase 2* ADCY2 Q08462-1 76.6134 0.8 0.346 Interaction
Possible
Adrenergic, beta, receptor kinase 1* ADRBK1 P25098-1 91.8466 0.75 0.343 Interaction
Possible
Amyloid beta (A4) precursor protein APP P05067-1 94.385 0.75 0.067 Interaction
Possible
Bone marrow stromal cell antigen 1 BST1 Q10588-1 88.2213 0.65 0.083 Interaction
Possible
Bone morphogenetic protein receptor, type II BMPR2 Q13873-1 76.283 0.8 0.146 Interaction
Possible
Bruton agammaglobulinemia tyrosine kinase BTK Q06187-1 84.8525 0.75 0.377 Interaction
Possible
Casein kinase 2, alpha 1 polypeptide CSNK2A1 P68400-1 74.3077 0.65 0.653 Interaction
Possible
Caveolin-1 CAV1 Q03135-1 77.9051 0.6 0.138 Interaction
Possible
Caveolin-2 CAV2 P51636-1 83.1315 0.6 0.219 Interaction
Possible
CD59 molecule CD59 P13987-1 82.6124 0.7 0.087 Interaction
Possible
Cysteine-rich, angiogenic inducer, 61 CYR61 O00622-1 89.9187 0.7 0.424 Interaction
Possible
DLC1 Rho gtpase activating protein DLC1 Q96QB1-2 78.2561 0.85 0.205 Interaction
Possible
Erb-b2 receptor tyrosine kinase 4* ERBB4 Q15303-1 88.6078 0.8 0.22 Interaction
Possible
Estrogen receptor 1 ESR1 P03372-1 82.6917 0.65 0.164 Interaction
Possible
Gap junction alpha-1 protein GJA1 P17302-1 71.9378 0.7 0.378 Interaction
Possible
Heat shock 70kda protein 5 HSPA5 P11021-1 87.4218 0.65 0.163 Interaction
Possible
Inhibitor of DNA binding 1, dominant negative helix-loop-
helix protein
ID1 P41134-1 63.6619 0.5 0.133 Interaction
Possible
Integrin, beta 1 ITGB1 P05556-1 91.4368 0.8 0.086 Interaction
Possible
Integrin, beta 8 ITGB8 P26012-1 91.3547 0.8 0.155 Interaction
Possible
Nitric oxide synthase trafficking NOSTRIN Q8IVI9-1 89.4255 0.65 0.063 Interaction
Possible
Phospholipase A2-activating protein PLAA Q9Y263-1 74.5552 0.7 0.199 Interaction
Possible
Platelet-derived growth factor receptor, alpha polypeptide PDGFRA P16234-1 77.8343 0.8 0.176 Interaction
Possible
Polymerase I and transcript release factor PTRF Q6NZI2-1 78.2171 0.7 0.201 Interaction
Possible
Prostaglandin-endoperoxide synthase 2 PTGS2 P35354-1 86.235 0.95 0.232 Interaction
Possible
Protein C receptor, endothelial PROCR Q9UNN8-1 88.6295 0.75 0.1 Interaction
Possible
Protein disulfide-isomerase A3 PDIA3 P30101-1 90.1417 0.85 0.583 Interaction
Possible
(Continued)
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Discussion
Numerous studies have identified biomarkers and molecular signatures aimed at improving
the diagnosis of mature T-cell lymphomas, herein we aimed to investigate shared molecular
underpinnings that can be attributed to all subtypes. Specifically, our study brings novel
insights into shared gene expression patterns (and confirmed protein expression of biopsy
samples) amongst a diverse group of mature T-cell lymphomas. Our analysis uncovered 21
genes that shared differential expression in comparison to healthy CD4+ and CD8+ T cells.
Together, these genes can be described as contributing to an activated phenotype, while sup-
pressing differentiation into mature, effector T cells. Additionally, shared methods of apoptotic
avoidance and ablations in TCR-related expression were observed.
Table 5. (Continued)
Protein Symbol UniProt Sequence
ID
lncPro1 RPISeq-
RF2
RPISeq-
SVM3
RPI-Pred
Protein kinase, camp-dependent, regulatory, type II,
alpha*
PRKAR2A P13861-1 93.0229 0.8 0.318 Interaction
Possible
Protein phosphatase 1, catalytic subunit, gamma isozyme PPP1CC P36873-1 63.2618 0.6 0.387 Interaction
Possible
Protein tyrosine phosphatase, non-receptor type 11 PTPN11 Q06124-1 78.559 0.6 0.022 Interaction
Possible
Ras homolog family member A RHOA P61586-1 66.3465 0.7 0.179 Interaction
Possible
RAS p21 protein activator RASA1 P20936-1 73.3972 0.65 0.263 Interaction
Possible
Scavenger receptor class B, member 2 SCARB2 Q14108-1 77.3416 0.6 0.086 Interaction
Possible
Serum deprivation response SDPR O95810-1 73.1867 0.5 0.104 Interaction
Possible
SMAD family member 5 SMAD5 Q99717-1 77.3416 0.75 0.096 Interaction
Possible
SMAD family member 7 SMAD7 O15105-1 75.7177 0.65 0.239 Interaction
Possible
SMAD family member 9 SMAD9 O15198-1 75.7465 0.6 0.147 Interaction
Possible
Son of sevenless homolog 1 SOS1 Q07889-1 91.8128 0.7 0.255 Interaction
Possible
Sterol carrier protein 2 SCP2 P22307-1 72.2967 0.75 0.071 Interaction
Possible
Striatin, calmodulin binding protein STRN O43815-1 75.5192 0.65 0.065 Interaction
Possible
Transmembrane emp24 domain trafficking protein 2 TMED2 Q15363-1 78.6391 0.8 0.327 Interaction
Possible
Transmembrane emp24-like trafficking protein 10 TMED10 P49755-1 89.2447 0.65 0.522 Interaction
Possible
Tumor necrosis factor receptor superfamily member 6 FAS P25445-1 92.6536 0.6 0.091 Interaction
Possible
Wiskott-Aldrich syndrome-like WASL O00401-1 83.887 0.55 0.228 Interaction
Possible
* Proteins in the CAV1-Low interaction network
1 Interactions scored positive at values 50
2 Interactions scored positive at values 0.5
3 Interactions scored positive at values 0.5
doi:10.1371/journal.pone.0142682.t005
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Regarding a shared activated phenotype for T-cell lymphomas, of the observed upregulated
genes, two (CAV1 and ENAH) have been implicated in cytoskeletal remodeling (and therefore,
cellular migration and immune synapse formation) following TCR-ligation [15, 26]. Knockout
studies of CAV1 that investigated immune synapse formation showed disruption of the actin
cytoskeleton [15] and deregulation of cell membrane polarity [27]. These studies indicated an
impairment of APC:T-cell engagement, and demonstrated a fundamental role for CAV1 as a
co-stimulatory molecule in immune synapse formation, though the precise mechanism
remains elusive. However, the upregulation of both CAV1 and ENAH could indicate an
enhancement of T-cell stimulation and activation. This observation is strengthened by a pan-
upregulation of TNFRSF21 (also known as DR6) and CCNB2. TNFRSF21 is a death domain-
containing receptor of the tumor necrosis factor-receptor family [28] shown to be upregulated
in peripheral CD4+ and CD8+ T cells following TCR-mediated T-cell activation in a time and
NF-kB/NFAT dependent manner [29]. CCNB2 is a G2/M specific cyclin kinetically shown to
be constantly upregulated throughout T cell stimulation [30].
Furthermore, the down regulation of TSC22D3 (also known as GILZ), TNFRSF14 (also
known as HVEM), CD5, and UBASH3A (also known as STS-2) are in accordance with an acti-
vated phenotype. GILZ (glucocorticoid-induced leucine zipper) is an NF-κB inhibitor that pre-
vents NF-κB binding and is independent from Rel- or I-κB-related proteins [31]. Additionally,
GILZ expression has been shown to be inversely correlated with T-cell activation [31, 32].
HVEM is down-regulated following T-cell activation, in concurrence with its description as a
negative regulator of T-cell activation. HVEM-/- mice displayed a hyper responsive phenotype
of enhanced proliferation and cytokine production (IFN-γ/IL-2) [33–35], a phenotype mir-
rored in STS-2-/- T cells [36]. CD5 has a demonstrated role in TCR-signaling wherein it acts as
a negative regulator through an immunoreceptor tyrosine-based inhibitory motif (ITIM)-like
motif [37]. The absence of CD5 in thymocytes induces a hyper-responsive state following
TCR-stimulation [38]. CD5 expression is routinely examined during histological staining of T-
cell lymphomas, and frequently harbors aberrant expression [13, 39, 40].
While displaying gene expression in accordance with an activated phenotype, all mature T-
cell lymphoma samples additionally differentially regulated genes involved in effector T-cell
differentiation (GILZ, TNFRSF21, STAT5A, RICTOR), T-cell homeostasis (FOXP1 and
HVEM), and upregulating an immature thymocyte marker (Thy-1/CD90) [41]. The upregula-
tion of TNFRSF21 and downregulation of GILZ, STAT5A, and RICTOR suggests a subversion
of Th2-effector differentiation as T cells displaying similar phenotypes harbored impairment of
Th2-cyotkine production or population homeostasis [42–45]. This observation suggests a
potential skewing of the neoplastic T cells towards other T-cell subsets or keeping them in an
undifferentiated state. For example, the cellular origin of AITL has been well studied and estab-
lished as follicular helper T cells [46–48]. Despite the established plasticity among helper T-cell
subsets, inter-subset regulation (i.e. maturation into one effector subset blocking the machinery
required for differentiation into other subsets) occurs regularly, and has been well described
[49]. Taken together, these data suggests that mature T-cell lymphomas display gene expres-
sion characteristics that subvert certain aspects of the Th2 effector phenotype. This indicates
that Th2 effector T cells may not represent a widespread cell-of-origin attributable to the
mature T-cell lymphoma subtypes analyzed. However, recent studies have shown that upregu-
lation of GATA3, the master transcription factor for Th2 effector T cells, is associated with a
poor prognosis [8, 50], demonstrating that a small subgroup of malignant Th2 cells exist, rep-
resenting a more aggressive disease phenotype.
Both FOXP1 and HVEM were found to be down-regulated in our analysis, and represent a
disruption of T-cell maturation and the homeostasis of mature, effector T cells. FOXP1 is a
member of the Forkhead box transcription factor family. FOXP1-deficient T cells display a
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premature activation phenotype in the thymus and the acquisition of effector functions. This
indicates an improper generation of quiescent, naïve T-cells [51, 52]. Further,HVEM-deficient
mice displayed a defect in the homeostasis of the long-term memory T-cell population and this
defect is independent of either Th1/Th2 populations [35]. Histological evaluation of FOXP1 in
T-cell lymphomas has demonstrated that higher FOXP1 expression leads to an improved over-
all survival in PTCL patients and may be associated with a less activated tumor phenotype [53].
However, FOXP1 staining has proven to have disparate results [54, 55] and not all T-cell lym-
phomas have been found to be immunoreactive to FOXP1 [55].
Thy-1 (CD90), a marker found to be upregulated in all mature T-cell lymphoma subtypes, is
a marker for thymus-derived lymphocytes in mice [56], with additional implications for being
a “cancer stem cell” marker present in both T- and B-malignancies due to its upregulation on
immature cells [41, 57, 58]. Additionally, CD90 has been described as a consistent marker in
different adult stem cell populations, reviewed in [59]. This observation is further supported by
inverse relationships noted between Thy-1 expression and T-cell differentiation or loss of
stem-cell like potential [41, 60], with T-cell expression of Thy-1 restricted to a small population
of cortical thymocytes in humans, in addition to staining in T cells surrounding germinal cen-
ters [61]. In our immunohistochemical analysis, 46% (29/65) of T-cell lymphoma samples
scored positive for CD90 lymphoid staining, with the staining being light and membranous.
These results are in agreement with the above-discussed immature/undifferentiated phenotype
observed in mature T-cell lymphomas, and suggest that these tumors may also increase the
amount of immature T-cells present within the lymph node microenvironment.
Down-regulations are observed for many genes involved in TCR-signaling and the proximal
events associated thereafter (CD3G, ITK, LAT, PAG1, PDE4B, PRKCQ). The attenuation of
TCR/CD3 complex protein expression and proximal signaling molecules is featured as a hall-
mark of ALCL [62–64] with similarities noted in CD30+ PTCL-NOS cases [55]. These demar-
cations were inferred from a lack of immunoreactivity in PTCL tissue samples. Here, we have
shown a down regulation of the mRNA of the aforementioned genes can be attributed to all
subtypes of mature T-cell lymphomas studied, but with markedly lower expression for some
genes in ALCL cases (Table 2). Further, ablations in TCR expression are seen with the down-
regulation of RICTOR, the scaffolding molecule for mTORC2 signaling. mTORC2 signaling is
vital for TCR surface expression, wherein RICTOR-deficient thymocytes displayed attenuated
TCR surface expression [65]. The dysregulation of the mTORC2 pathway is further validated
by the observed down-regulation of TCR components (TRAC, TRBC1) and stabilizing mole-
cules (TRAT1) seen across multiple T-cell lymphoma subtypes (S1 Table).
For genes involving in apoptotic resistance and immune evasion, we observed a down-regu-
lation of IL23A, and upregulation of PSEN2. IL23 is an immunomodulatory cytokine with con-
troversial findings in terms of its anti-tumor properties [66, 67]. Despite this, IL23 has been
described as effective in its activity against B-cell malignancies both in vitro and in vivo [68,
69]. Down-regulation of IL23A by T-cell malignancies represents a potential mechanism of
immune evasion, which is further supported by an observed down-regulation of IL12RB1 (seen
in all subtypes except ALCL, S1 Table), a component of the IL23 receptor [70]. PSEN2 is upre-
gulated during some forms of apoptosis [71, 72], however its cleavage by caspase-3 (upregu-
lated in all but AITL, S1 Table) results in a peptide fragment starting a negative feedback loop
and inhibiting apoptosis [73]. These mechanisms of apoptotic avoidance represent potential
therapeutic targets for further studies as α-IL23 has demonstrated activity against B-cell
malignancies.
Using the top-scoring pairs method [18], the expression differential between CAV1 and
BCL10 identified lymphoma samples with 98.4% sensitivity and 88.5% specificity. While the
selection of CAV1 and BCL10 by the TSP method was a priori, the available genes were selected
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due to their differential expression, introducing bias. However, the CAV1/BCL10 ratio is bio-
logically relevant, with a prior inverse correlation observed in CAV1-/- T-lymphocytes [74],
and BCL10 being downstream of CD26 signaling, of which CAV1 is the cognate ligand [75].
BCL10 has been prior described as down-regulated among T-cell lymphomas, an observation
in accordance with our findings. Despite this, the exact role for BCL10 is still inconclusive [39,
76, 77]. Our results demonstrate interplay between CAV1 and BCL10 in T-cell lymphomas
and warrants further investigation.
In our analyses, CAV1 was upregulated in each T-cell lymphoma subtype. Since CAV1 is
linked to disease progression and metastasis in different malignancies [15, 78–83], we sought
to investigate the role of CAV1 within the tumor microenvironment. PANTHER gene list anal-
ysis of CAV1-High versus CAV1-Low malignancies revealed an enrichment of multiple GO
annotations for cytokine/chemokine activity, immune processes, and migration/motility within
the CAV1-High group. The existence of the heterogeneity of CAV1expression in T-cell lym-
phomas was further solidified with our immunohistochemical results, with 55% (36/65) of
tumor biopsies harboring lymphoid staining of CAV1. Taken together, these data suggest that
T-cell malignancies with higher CAV1 expression correlate with a GEP of possessing a more
inflammatory tumor microenvironment and may hold more metastatic potential [78, 82, 83].
Further support for this is seen in the CAV1-protein networks determined by STRING. These
networks displayed enrichment in proteins involved in cell migration and proliferation, indi-
cating that CAV1 is directly involved in the aforementioned signaling processes and is an inte-
gral protein driving the differences within the CAV1-High and CAV1-Low tumor
microenvironments. However, further analysis is required for confirmation of a role for CAV1
in disease progression in T-cell lymphomas. Chiefly, detailed research involving patient records
and clinical characteristics is needed for a definitive conclusion. Such a study would be in-line
with the current knowledge of CAV1 expression within malignant entities, and is warranted
based on the abovementioned results.
Interestingly, we also observed a long non-coding RNA (LINC00273) to be one of the high-
est genes differentially expressed between the CAV1-High and CAV1-Low groups. As long
non-coding RNA signatures have been previously shown to be predictive in cancer [84–87], we
chose to investigate whether this long non-coding RNA harbored any potential interactions
with CAV1, given that CAV1 was the basis upon which sample stratification was conducted.
Surprisingly, using computational prediction methods, we show that LINC00273 is predicted
to interact with CAV1 and members of a CAV1-interaction network in 3 out of 4 prediction
metrics. The large discrepancy regarding RPISeq results could stem from the RPISeq-SVM
having a lower accuracy in H. Sapiens non-coding RNA-protein interaction prediction (57.3%)
as compared to RPISeq-RF (74.7%) [24]. While we observe a greater inconsistency in our data
regarding prediction, both lncPro and RPIPred achieved a consensus prediction with the more
accurate RPISeq-RF. Protein-RNA networks have been demonstrated as indispensible for cel-
lular homeostasis [88–90], and the further investigation of long non-coding RNA signatures in
T-cell lymphomas might hold predictive or therapeutic implications.
Herein, we present novel work concerning shared molecular underpinnings of five subtypes
of mature T-cell lymphomas. These results enhance the knowledge of the basic biology of T-
cell lymphomas, leading to insights concerning their activation and differentiation states, while
also uncovering novel markers for future study. Finally, we characterize a role for CAV1 within
the tumor microenvironment, wherein higher CAV1 expression among mature T-cell lympho-
mas coincides with a more inflammatory and invasive gene expression profile. Future study
investigating the clinical implications of CAV1 expression in mature T-cell lymphomas is
warranted.
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Materials and Methods
Ethics statement
All patient samples used within this study were from publicly available databases (i.e. gene
expression samples) or commercial vendors (i.e. histology samples). Any and all patient disclo-
sures were conducted within the original studies from which these samples were taken. The
authors of this study state that they have neither tracing nor identification information that
would disclose the identity of the patient samples herein.
Data collation and normalization
Raw (.CEL) files were downloaded from the NCBI Gene Expression Omnibus (GEO) and
loaded into BRB-ArrayTools using MAS5.0 normalization [91]. All samples were from publi-
cally available studies, as described in Table 1. In total, 52 healthy T-cell samples including:
CD4+ T cells and CD8+ T cells taken from peripheral blood donors, and 187 non-treated,
lymph node or splenic T-cell lymphoma biopsy samples were analyzed. All samples collated
were prepared using HG-U133 plus 2 arrays. Replicate spots within arrays were averaged and
multiple probes/probe sets were reduced to one per gene symbol using the maximally
expressed probe (set) as measured by average intensity across arrays. Cell line samples, samples
from non-lymphoid tissue, and samples not of interest to this study (e.g. B-cell samples and
reactive tonsil samples) from the aforementioned datasets were discarded.
T-cell compartment signature
To investigate the T-cell compartments of the malignant lymphoma samples, a “T-cell com-
partment signature” was created to be used in analyses of differential expression, thereby help-
ing to reduce expression signatures from stromal components generated by processing whole
tumor biopsies. This signature was compiled from GO annotation sets for T-cell receptor sig-
naling, T-cell co-stimulation, T-cell homeostasis, and T-cell differentiation (http://
geneontology.org/). Upon merging annotation lists, excluding duplicate genes, and manual
curation for genes not expressed in T cells, 217 unique genes met these criteria (S4 Table).
T-cell compartment differential expression analysis
For analysis of the differentially expressed genes between the T-cell compartment of malignant
samples and healthy controls, the class comparison method among groups of arrays was used
with the Multivariate Permutations test computed based on 1,000 random permutations.
Genes were filtered according to the compiled T-cell compartment signature (see T-Cell Com-
partment Signature above) and results were deemed significant at p< 0.001, with a false dis-
covery rate (FDR) of< 0.001. Each malignant subtype was analyzed separately followed by
manual analysis of shared differentially expressed genes between each subtype as compared to
healthy controls. Manual compilation allowed for the construction of a shared list of differen-
tially expressed genes shared across each subtype.
Establishment of a CAV1-expression threshold
To stratify malignant samples that overexpress CAV1, all samples were analyzed for CAV1
expression via the 212097_at probe signal. A CAV1 expression threshold was calculated by tak-
ing two standard deviations above the mean of the CAV1 expression signal in healthy samples.
Ninety-two percent (92%, 48/52) of healthy samples were below the calculated threshold, com-
prising 100% of non-outlier samples (identified as dots above the upper fence on the box-and-
whisker plot). This threshold was selected as an adaptation of the 68-95-99.7 standard
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deviation short hand. While the healthy CAV1 expression range did not follow a normal distri-
bution, two standard deviations from the mean covered the abovementioned 92% of samples
and the remaining 7% comprised outliers. This threshold was deemed acceptable as it classified
all non-outlier samples within the healthy range and moving the threshold to three standard
deviations exceeded all values within the healthy population. Malignant samples that were
above the expression threshold were categorized as “CAV1-High”, while malignant samples
below the expression threshold were categorized as “CAV1-Low”.
CAV1-High versus CAV1-Low differential expression analysis
For analysis of the tumor microenvironment of CAV1-High and CAV1-Low samples, only
genes with a significant (p< 0.01) correlation (“R” cut-off ± 0.22) to CAV1 expression were
included (n = 7,170) to reduce inter-malignancy variation. Differentially expressed genes
(p< 0.001) were then determined using the class comparison among groups of arrays method
with the Multivariate Permutations test computed based on 1,000 random permutations and a
restriction on the proportion of false discoveries set at 1% with a confidence level of 99%.
Gene list analysis of CAV1-High vs CAV1-Low
Fold-change values for genes found to be differentially expressed between the CAV1-High and
CAV1-Low groups were input into the PANTHER gene analysis tool (PANTHER version 9.0;
http://pantherdb.org/) [19, 20]. PANTHER enrichment and overrepresentation (excluding
genes downregulated in CAV1-High) analyses were performed using theHomo sapiens refer-
ence list. Annotation data sets utilized included: GOmolecular function, biological process, cel-
lular component (complete versions), PANTHER protein class, and PANTHER pathways.
Results were deemed significant at p< 0.05 using the Bonferroni correction method.
CAV1-interaction networks
Genes upregulated in the CAV1-High and CAV1-Low expression groups were input separately
into STRING v10 [92] to identify potential CAV1 protein-protein interaction networks. Inter-
action network constituents were determined by visual analysis of proteins shown to have
direct or indirect interaction with CAV1. Enrichment analyses were conducted using the
genome background and Bonferroni correction with results deemed significant at p< 0.001.
Long non-coding RNA-protein interaction prediction
Long non-coding RNA-protein interaction (RPI) was predicted using three separate programs:
lncPro [23], RPISeq [24], and RPI-Pred [25]. As RPISeq offers two prediction methods, a total
of 4 distinct prediction outcomes were computed. RPI prediction software inputs were com-
piled according to program specificity. For lncPro, FASTA amino acid sequences for CAV1-in-
teracting proteins, in addition to the FASTA nucleotide sequence for LINC00273, were input
into the lncPro web-based platform (http://bioinfo.bjmu.edu.cn/lncpro/). The same protocol
was used for the RPISeq web-based platform (http://pridb.gdcb.iastate.edu/RPISeq/). Equivocal
information is required for the RPI-Pred platform (http://ctsb.is.wfubmc.edu/projects/rpi-
pred/), in addition to protein block (PB) information [93]. As not all structures have been
experimentally solved for the proteins of interest, the kPRED method [94] of PB structure pre-
diction was used identical to Suresh et al. [25]. Per the literature, lncPro predictions were
deemed positive for interaction scores 50, RPISeq for interaction scores 0.5, and RPI-Pred
supplied text-based interpretations.
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Tissue microarray immunohistochemical staining
LY6161 high-density lymphoma and normal lymph node tissue arrays were ordered from U.S.
Biomax, Inc and stained using the following protocol. Tissue array slides were deparaffinized
and hydrated through xylene and a graded alcohol series, rinsed for 5 minutes in water, and
incubated for 5 minutes in 3% H2O2. Slides were then washed 2 times followed by antigen
unmasking using 1x antigen unmasking solution (Vector Laboratories) for 30 minutes. Slides
were allowed to cool, washed 3 times in 0.1% Tween-20 PBS buffer, and blocked for 30 minutes
with 2.5% normal horse blocking serum (Vector Laboratories). Slides were then stained with
antibodies directed against BCL10 (1:100), CD90 (1:10), CAV1 (1:100), and GILZ (1:50), over-
night at 4°C. Slides were subsequently washed 3 times, incubated for 30 minutes with Imm-
PRESS™ reagent (Vector Laboratories), and washed an additional 3 times. Staining was
revealed in peroxidase substrate DAB solution, with rinsing in tap water. Slides were counter-
stained with Hematoxylin QS (Vector Laboratories) and mounted with permanent mounting
medium (Sigma).
Immunohistochemical staining analysis
Stained slides were scanned using an iScan Coreo Au whole slide brightfield slide scanner
(Ventana) and visualized using Ventana Image Viewer. Four independent researchers scored
the slides based on the presence or absence of staining in lymphoid cells and/or the presence or
absence of staining in stromal/non-lymphoid cells.
Supporting Information
S1 Fig. PANTHER enrichment analysis of the integrin signaling pathway.Molecule colors
represent fold-change values (CAV1-High vs CAV1-Low): (dark blue = -3.361E00 to
-1.536E00); (light blue = -1.536 to 1.542); (green = 1.542 to 1.715); (yellow = 1.715 to 1.882);
(orange = 1.882 to 2.117); (red = 2.117 to 5.099).
(TIF)
S2 Fig. PANTHER overrepresentation analysis for the PANTHER pathway: inflammation
mediated by chemokine and cytokine signaling. Genes upregulated in CAV1-High samples
as opposed to CAV1-Low are represented in red, while genes in the reference list are repre-
sented in gray.
(TIF)
S3 Fig. PANTHER overrepresentation analysis for the PANTHER pathway: angiogenesis.
Genes upregulated in CAV1-High samples as opposed to CAV1-Low are represented in red,
while genes in the reference list are represented in gray.
(TIF)
S1 Table. Genes significantly up- or down-regulated in at least 3/5 of T-cell lymphoma sub-
types.
(DOCX)
S2 Table. Top-scoring pairs classification results.
(DOCX)
S3 Table. Detailed analysis of immunohistochemical staining on individual TMA samples.
(DOCX)
S4 Table. Genes comprising the T-cell compartment.
(DOCX)
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